Competing interest:
The author declares no competing interests regarding this study.
1. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger
D, Cavenee WK, et al. The 2016 World Health Organization Classification
of Tumors of the Central Nervous System: a summary. Acta Neuropathol.
2016;131(6):803-20.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ,
et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med. 2005;352(10):987-96.
3. Koshy M, Villano JL, Dolecek TA, Howard A, Mahmood U, Chmura SJ, et
al. Improved survival time trends for glioblastoma using the SEER 17
population-based registries. J Neurooncol. 2012;107(1):207-12.
4. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al.
Identification of human brain tumour initiating cells. Nature.
2004;432(7015):396-401.
5. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, et al.
Stem cell-like glioma cells promote tumor angiogenesis through vascular
endothelial growth factor. Cancer Res. 2006;66(16):7843-8.
6. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma
stem cells promote radioresistance by preferential activation of the DNA
damage response. Nature. 2006;444(7120):756-60.
7. Mizutani T, Taniguchi Y, Aoki T, Hashimoto N, Honjo T. Conservation
of the biochemical mechanisms of signal transduction among mammalian
Notch family members. Proc Natl Acad Sci U S A. 2001;98(16):9026-31.
8. Nickoloff BJ, Osborne BA, Miele L. Notch signaling as a therapeutic
target in cancer: a new approach to the development of cell fate
modifying agents. Oncogene. 2003;22(42):6598-608.
9. Iso T, Kedes L, Hamamori Y. HES and HERP families: multiple effectors
of the Notch signaling pathway. J Cell Physiol. 2003;194(3):237-55.
10. Takebe N, Nguyen D, Yang SX. Targeting notch signaling pathway in
cancer: clinical development advances and challenges. Pharmacol Ther.
2014;141(2):140-9.
11. Pan E, Supko JG, Kaley TJ, Butowski NA, Cloughesy T, Jung J, et al.
Phase I study of RO4929097 with bevacizumab in patients with recurrent
malignant glioma. J Neurooncol. 2016;130(3):571-9.
12. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, et al.
Analysis of gene expression and chemoresistance of CD133+ cancer stem
cells in glioblastoma. Mol Cancer. 2006;5:67.
13. Fan X, Matsui W, Khaki L, Stearns D, Chun J, Li YM, et al. Notch
pathway inhibition depletes stem-like cells and blocks engraftment in
embryonal brain tumors. Cancer Res. 2006;66(15):7445-52.
14. Xu R, Shimizu F, Hovinga K, Beal K, Karimi S, Droms L, et al.
Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A
Phase 0/I Trial. Clin Cancer Res. 2016;22(19):4786-96.
15. Bolós V, Blanco M, Medina V, Aparicio G, Díaz-Prado S, Grande E.
Notch signalling in cancer stem cells. Clin Transl Oncol.
2009;11(1):11-9.